2025年咪达那新片正版的价格是多少？

Imidafenacin is an anticholinergic drug for overactive bladder, developed and produced by Japan's Kyorin Pharmaceuticals. In 2025, its genuine price will be approximately US$72, with a specification of 0.1mg*100 tablets/box. This article will introduce in detail the price information, usage and dosage of midanacin tablets, as well as medication precautions for special groups, to help readers fully understand the clinical application of this drug.

What is the price of the genuine version of Midanax in 2025?

The genuine price will remain stable in 2025 and is mainly sold in the Japanese market. Its price and specification information are particularly important for patients who require long-term medication. The following prices are for reference only.

Price and Specifications

The price of both the regular version and the OD version of the new midana tablets is US$72 per box. Each box contains 100 tablets, and the dosage of each tablet is 0.1mg. As of now, midanacin tablets have not been launched in China, so domestic patients need to purchase them through other channels.

Market Current Situation

The new Midana tablets have not yet been included in China’s medical insurance, and there are no generic drugs on the market. For patients who require long-term treatment, purchasing genuine drugs is the only option.

Understanding the price information of midanacin tablets will help patients make a budget for their medication, while also paying attention to its launch progress in the Chinese market.

Usage and dosage of Midanacin Tablets

The usage and dosage of Midanacin Tablets must be strictly followed by the doctor's instructions to reduce the occurrence of adverse reactions.

Regular adult dosage

Adult patients take 0.1mg each time, twice a day, orally after breakfast and dinner. If the efficacy is not good and the safety profile is normal, it can be increased to 0.2 mg each time, but the maximum daily dose shall not exceed 0.4 mg.

Adjustment for special groups

Patients with moderate or above moderate liver function impairment and patients with severe renal impairment need to adjust the dosage to 0.1 mg each time, twice a day. Elderly patients also need to closely monitor adverse reactions due to decline in physiological functions and adjust the dose if necessary.

Patients must strictly follow the doctor's instructions and use the medication correctly, and are not allowed to increase or decrease the dosage of the medication at will.

Use of Midanacin Tablets in Special Populations

Use of Midanacin Tablets in special populations requires extreme caution to avoid potential risks.

Pregnant and lactating women

It is not recommended to use midanacin tablets for pregnant women or those who may be pregnant. They should only be used with caution when the benefits of treatment outweigh the risks. Breastfeeding women need to weigh the pros and cons of treatment and breastfeeding, and suspend breastfeeding if necessary.

Children and the Elderly

Safety and effectiveness in pediatric patients have not been established and use is not recommended. The physiological functions of the elderly decline, which may lead to delayed drug excretion due to decreased renal function, and adverse reactions need to be closely monitored.

Medications for special groups need to be combined with individual conditions and the dosage should be adjusted or alternative treatment options selected under the guidance of a doctor.